Home Metabolism LDL

LDL

LDL Products

  • All (7)
  • LDL Inhibitor (1)
  • LDL Antibodie (1)
  • LDL Modulators (5)
  • New LDL Products
Catalog No. Product Name Information Product Use Citations Product Validations
S1655 Ezetimibe (SCH-58235) Ezetimibe (SCH-58235) is a potent, selective, cholesterol absorption inhibitor, used to lower cholesterol.
J Immunother Cancer, 2024, 12(11)e009805
EMBO Mol Med, 2022, 14(2):e14903
Exp Hematol Oncol, 2022, 11(1):51
S2748 Anacetrapib (MK-0859) Anacetrapib (MK0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure. Phase 3.
Circulation, 2021, 143(9):921-934
J Phys Chem B, 2016, 120(33):8254-63
Atherosclerosis, 2014, 235(2):449-62
S7953 Bempedoic acid (ETC-1002) Bempedoic acid (ETC-1002),also known as Bempedoic acid, is an orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies.ETC-1002 is an activator of hepatic AMP-activated protein kinase (AMPK). It has potent inhibitory activity against hepatic ATP-citrate lyase(IC50=29 uM).
iScience, 2023, 26(12):108532
Oncol Rep, 2023, 49(2)32
Biomed Pharmacother, 2021, 144:112325
S2119 Probucol Probucol (DH-581) is an anti-hyperlipidemic drug by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.
J Immunother Cancer, 2024, 12(11)e009805
Int Immunopharmacol, 2023, 116:109820
E3811 Cashew Extract Cashew Extract is extracted from Anacardium occidentale, which lowers the levels of LDL cholesterol and may help to prevent heart disease due to its high magnesium content.
A2386 Orticumab (Anti-oxLDL) Orticumab (MLDL1278A) is an antibody targeting oxidized or malondialdehyde-modified lipoprotein (LDL) that specifically inhibits oxidised low-density lipoproteins (oxLDL). Orticumab is involved in the modulation of autoimmune responses against oxLDL and improves atherosclerosis in an animal model. MW: 145.5 kD.
S9187 Phillygenin Phillygenin (Sylvatesmin), a bioactive intergradient in Osmanthus fragrans, has anti-inflammatory, anti-obesity and antipyretic activities. It could reduce blood lipid levels and low density lipoprotein.
E3811 Cashew Extract Cashew Extract is extracted from Anacardium occidentale, which lowers the levels of LDL cholesterol and may help to prevent heart disease due to its high magnesium content.
A2386 Orticumab (Anti-oxLDL) Orticumab (MLDL1278A) is an antibody targeting oxidized or malondialdehyde-modified lipoprotein (LDL) that specifically inhibits oxidised low-density lipoproteins (oxLDL). Orticumab is involved in the modulation of autoimmune responses against oxLDL and improves atherosclerosis in an animal model. MW: 145.5 kD.
S1655 Ezetimibe (SCH-58235) Ezetimibe (SCH-58235) is a potent, selective, cholesterol absorption inhibitor, used to lower cholesterol.
J Immunother Cancer, 2024, 12(11)e009805
EMBO Mol Med, 2022, 14(2):e14903
Exp Hematol Oncol, 2022, 11(1):51
S2748 Anacetrapib (MK-0859) Anacetrapib (MK0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure. Phase 3.
Circulation, 2021, 143(9):921-934
J Phys Chem B, 2016, 120(33):8254-63
Atherosclerosis, 2014, 235(2):449-62
S7953 Bempedoic acid (ETC-1002) Bempedoic acid (ETC-1002),also known as Bempedoic acid, is an orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies.ETC-1002 is an activator of hepatic AMP-activated protein kinase (AMPK). It has potent inhibitory activity against hepatic ATP-citrate lyase(IC50=29 uM).
iScience, 2023, 26(12):108532
Oncol Rep, 2023, 49(2)32
Biomed Pharmacother, 2021, 144:112325
S2119 Probucol Probucol (DH-581) is an anti-hyperlipidemic drug by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.
J Immunother Cancer, 2024, 12(11)e009805
Int Immunopharmacol, 2023, 116:109820
S9187 Phillygenin Phillygenin (Sylvatesmin), a bioactive intergradient in Osmanthus fragrans, has anti-inflammatory, anti-obesity and antipyretic activities. It could reduce blood lipid levels and low density lipoprotein.

Choose Selective LDL Inhibitors

Tags: LDL modulation | LDL modulator | LDL regulation| LDL review